[{"id":"79649cc6-d582-4cf7-94a7-6b84b6103cab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04901702","created_at":"2021-05-25T18:52:49.387Z","updated_at":"2025-02-25T12:28:07.986Z","phase":"Phase 1/2","brief_title":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","source_id_and_acronym":"NCT04901702","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" EWSR1 • FLI1","pipe":"","alterations":" ","tags":["EWSR1 • FLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Talzenna (talazoparib) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 06/09/2021","start_date":" 06/09/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"c5baf3d3-95f8-46cc-89ee-2ac65d9ade70","acronym":"","url":"https://clinicaltrials.gov/study/NCT06023641","created_at":"2023-09-05T18:12:33.949Z","updated_at":"2025-02-25T12:29:46.532Z","phase":"Phase 1/2","brief_title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","source_id_and_acronym":"NCT06023641","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TP53 • FOXO1 • MYOD1","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • FOXO1 • MYOD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • cyclophosphamide • vincristine • vinorelbine tartrate • dactinomycin • Onivyde (nanoliposomal irinotecan) • Navelbine oral (vinorelbine tartrate oral) • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/13/2024","start_date":" 03/13/2024","primary_txt":" Primary completion: 10/01/2034","primary_completion_date":" 10/01/2034","study_txt":" Completion: 10/01/2037","study_completion_date":" 10/01/2037","last_update_posted":"2025-02-24"},{"id":"c3ccbe27-3d9e-4190-a952-e531da2607f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04890093","created_at":"2021-05-18T12:01:54.563Z","updated_at":"2025-02-25T13:49:09.588Z","phase":"Phase 1/2","brief_title":"Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT04890093","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • vincristine • locnartecan (PEN-866)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 10/31/2024","start_date":" 10/31/2024","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-20"},{"id":"cce0df20-21d8-4bec-947f-b02d39935805","acronym":"ARST2031","url":"https://clinicaltrials.gov/study/NCT04994132","created_at":"2023-08-27T06:10:56.547Z","updated_at":"2025-02-25T14:08:23.955Z","phase":"Phase 3","brief_title":"A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma","source_id_and_acronym":"NCT04994132 - ARST2031","lead_sponsor":"Children's Oncology Group","biomarkers":" FOXO1","pipe":"","alterations":" ","tags":["FOXO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • vincristine • dactinomycin • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-18"},{"id":"33cb5dea-96fe-4042-acd6-5536453b01bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05304585","created_at":"2023-08-27T06:11:07.562Z","updated_at":"2025-02-25T15:12:43.166Z","phase":"Phase 3","brief_title":"Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma","source_id_and_acronym":"NCT05304585","lead_sponsor":"Children's Oncology Group","biomarkers":" FOXO1","pipe":"","alterations":" ","tags":["FOXO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • vincristine • dactinomycin"],"overall_status":"Recruiting","enrollment":" Enrollment 205","initiation":"Initiation: 08/04/2022","start_date":" 08/04/2022","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2030","study_completion_date":" 06/30/2030","last_update_posted":"2025-02-13"},{"id":"d38d93a5-1599-4b68-93ad-26dfc09858e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04796012","created_at":"2021-03-12T15:52:59.385Z","updated_at":"2025-02-25T15:12:00.891Z","phase":"Phase 1/2","brief_title":"VITAS: Atezolizumab in Combination with Chemotherapy for Pediatric Relapsed/refractory Solid Tumors","source_id_and_acronym":"NCT04796012","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • temozolomide • irinotecan • vincristine"],"overall_status":"Recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-13"},{"id":"a960e964-3a5f-401a-844c-ae8dd61b3da6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213704","created_at":"2023-12-06T19:15:43.766Z","updated_at":"2025-02-25T16:51:56.748Z","phase":"Phase 2","brief_title":"Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213704","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 08/23/2017","start_date":" 08/23/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 10/08/2025","study_completion_date":" 10/08/2025","last_update_posted":"2025-02-04"},{"id":"d16edb9e-05b0-4a67-8757-e2748c115c02","acronym":"ARST1431","url":"https://clinicaltrials.gov/study/NCT02567435","created_at":"2024-01-09T20:20:40.495Z","updated_at":"2025-02-25T16:51:34.054Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","source_id_and_acronym":"NCT02567435 - ARST1431","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FOXO1 • PAX3 • PAX7","pipe":"","alterations":" ","tags":["FOXO1 • PAX3 • PAX7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • irinotecan • temsirolimus • vincristine • vinorelbine tartrate • dactinomycin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 325","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 10/16/2025","study_completion_date":" 10/16/2025","last_update_posted":"2025-02-04"},{"id":"e098103f-75c1-4aa9-b386-41c1d51fb602","acronym":"MATCH","url":"https://clinicaltrials.gov/study/NCT03155620","created_at":"2021-01-18T15:33:32.929Z","updated_at":"2025-02-25T16:51:52.930Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","source_id_and_acronym":"NCT03155620 - MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2316","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-04"},{"id":"6365efdc-854e-4454-ba10-f28f09a5a11b","acronym":"PEPN2112","url":"https://clinicaltrials.gov/study/NCT05071209","created_at":"2021-10-08T11:53:44.641Z","updated_at":"2025-02-25T17:01:24.348Z","phase":"Phase 1/2","brief_title":"Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT05071209 - PEPN2112","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3","pipe":" | ","alterations":" PAX3-FOXO1 fusion","tags":["BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PAX3-FOXO1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elimusertib (BAY 1895344)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 12/22/2021","start_date":" 12/22/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 11/22/2025","study_completion_date":" 11/22/2025","last_update_posted":"2025-02-03"},{"id":"96a46201-6c05-499a-b5e8-480c4ba52158","acronym":"","url":"https://clinicaltrials.gov/study/NCT03382158","created_at":"2021-01-18T16:41:19.886Z","updated_at":"2025-02-25T17:29:36.962Z","phase":"","brief_title":"International PPB/DICER1 Registry","source_id_and_acronym":"NCT03382158","lead_sponsor":"Children's Hospitals and Clinics of Minnesota","biomarkers":" DICER1","pipe":"","alterations":" ","tags":["DICER1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 3400","initiation":"Initiation: 12/06/2016","start_date":" 12/06/2016","primary_txt":" Primary completion: 12/06/2030","primary_completion_date":" 12/06/2030","study_txt":" Completion: 12/06/2035","study_completion_date":" 12/06/2035","last_update_posted":"2025-01-30"},{"id":"0811eebd-2541-4c17-9f6e-9259710f1407","acronym":"TARGET-RT","url":"https://clinicaltrials.gov/study/NCT06796543","created_at":"2025-02-25T16:28:16.453Z","updated_at":"2025-02-25T16:28:16.453Z","phase":"","brief_title":"Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma","source_id_and_acronym":"NCT06796543 - TARGET-RT","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" EFS","pipe":"","alterations":" ","tags":["EFS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-01-29"},{"id":"d9dd8a9e-c9dc-461e-aece-5bc7f49d536e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03709680","created_at":"2021-11-09T18:05:08.609Z","updated_at":"2024-07-02T16:35:02.132Z","phase":"Phase 1/2","brief_title":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","source_id_and_acronym":"NCT03709680","lead_sponsor":"Pfizer","biomarkers":" EWSR1 • FUS","pipe":"","alterations":" ","tags":["EWSR1 • FUS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • temozolomide • cyclophosphamide • irinotecan • topotecan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 05/24/2019","start_date":" 05/24/2019","primary_txt":" Primary completion: 06/24/2024","primary_completion_date":" 06/24/2024","study_txt":" Completion: 02/25/2025","study_completion_date":" 02/25/2025","last_update_posted":"2024-05-22"},{"id":"1ba7d423-e8de-4bf4-9f12-f7ec8c7c5db7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03526250","created_at":"2021-01-18T17:22:05.437Z","updated_at":"2024-07-02T16:35:02.332Z","phase":"Phase 2","brief_title":"Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03526250","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-05-21"},{"id":"6f199ca7-66c7-422b-8786-948a1a709536","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213678","created_at":"2021-01-18T15:51:26.276Z","updated_at":"2024-07-02T16:35:02.372Z","phase":"Phase 2","brief_title":"Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213678","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • TSC2 • TSC1","pipe":" | ","alterations":" PTEN expression • TSC1 mutation • TSC2 mutation","tags":["PTEN • TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression • TSC1 mutation • TSC2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/28/2017","start_date":" 11/28/2017","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-05-21"},{"id":"1a3cab9e-cdcf-4503-89c5-149536f7d547","acronym":"ADVL1622","url":"https://clinicaltrials.gov/study/NCT02867592","created_at":"2021-01-18T14:04:35.391Z","updated_at":"2024-07-02T16:35:02.779Z","phase":"Phase 2","brief_title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","source_id_and_acronym":"NCT02867592 - ADVL1622","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET • RET • AXL","pipe":" | ","alterations":" MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression","tags":["MET • RET • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 05/18/2017","start_date":" 05/18/2017","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-05-17"},{"id":"82dcc018-99ce-47f7-8c3b-045c9ebf3e1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03220035","created_at":"2021-01-18T15:53:33.764Z","updated_at":"2024-07-02T16:35:02.750Z","phase":"Phase 2","brief_title":"Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03220035","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4","initiation":"Initiation: 11/08/2017","start_date":" 11/08/2017","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-05-17"},{"id":"a50db79e-f985-4b65-9c1b-fc575cc8904a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04715191","created_at":"2021-01-21T06:52:06.961Z","updated_at":"2024-07-02T16:35:05.923Z","phase":"Phase 1","brief_title":"Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors","source_id_and_acronym":"NCT04715191","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • GLYCAR T cells • GPC3-CAR and IL15 plus IL21 • cyclophosphamide intravenous"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/03/2024","start_date":" 07/03/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 07/03/2041","study_completion_date":" 07/03/2041","last_update_posted":"2024-05-06"},{"id":"84a8bbc2-ef05-45fb-8d2a-c2429e123035","acronym":"STRIvE-02","url":"https://clinicaltrials.gov/study/NCT04483778","created_at":"2021-01-18T21:31:43.742Z","updated_at":"2024-07-02T16:35:07.947Z","phase":"Phase 1","brief_title":"B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT04483778 - STRIvE-02","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression • CD19 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2040","study_completion_date":" 12/01/2040","last_update_posted":"2024-04-23"},{"id":"27578ddc-f283-4d0d-bcd4-108743a5b2fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04530487","created_at":"2021-01-18T21:41:28.381Z","updated_at":"2024-07-02T16:35:10.209Z","phase":"Phase 2","brief_title":"Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults","source_id_and_acronym":"NCT04530487","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • melphalan • fludarabine IV • thiotepa • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/19/2020","start_date":" 08/19/2020","primary_txt":" Primary completion: 05/09/2025","primary_completion_date":" 05/09/2025","study_txt":" Completion: 05/09/2025","study_completion_date":" 05/09/2025","last_update_posted":"2024-04-11"},{"id":"e1485158-d730-462d-be42-9cd0f137d814","acronym":"STRIvE-01","url":"https://clinicaltrials.gov/study/NCT03618381","created_at":"2021-01-18T17:46:54.866Z","updated_at":"2024-07-02T16:35:10.845Z","phase":"Phase 1","brief_title":"EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT03618381 - STRIvE-01","lead_sponsor":"Seattle Children's Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 06/18/2019","start_date":" 06/18/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2040","study_completion_date":" 06/01/2040","last_update_posted":"2024-04-09"},{"id":"fca0acc3-ee52-4102-a447-7fd22d0a32ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT02162732","created_at":"2021-01-18T10:04:10.523Z","updated_at":"2024-07-02T16:35:11.152Z","phase":"","brief_title":"Molecular-Guided Therapy for Childhood Cancer","source_id_and_acronym":"NCT02162732","lead_sponsor":"Giselle Sholler","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"],"overall_status":"Completed","enrollment":" Enrollment 186","initiation":"Initiation: 07/08/2014","start_date":" 07/08/2014","primary_txt":" Primary completion: 01/18/2024","primary_completion_date":" 01/18/2024","study_txt":" Completion: 01/18/2024","study_completion_date":" 01/18/2024","last_update_posted":"2024-04-05"},{"id":"fe1ac180-6f98-4398-8969-e53c96e38efd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01386619","created_at":"2021-01-18T05:41:22.366Z","updated_at":"2024-07-02T16:35:14.091Z","phase":"Phase 1/2","brief_title":"NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)","source_id_and_acronym":"NCT01386619","lead_sponsor":"University Hospital, Basel, Switzerland","biomarkers":" NCAM1","pipe":"","alterations":" ","tags":["NCAM1"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 01/01/2004","start_date":" 01/01/2004","primary_txt":" Primary completion: 03/01/2011","primary_completion_date":" 03/01/2011","study_txt":" Completion: 03/01/2011","study_completion_date":" 03/01/2011","last_update_posted":"2024-03-19"},{"id":"ffe96379-a55d-4c21-b2bf-0bb984a6f16f","acronym":"STIR Trial","url":"https://clinicaltrials.gov/study/NCT02100891","created_at":"2021-01-18T09:42:21.170Z","updated_at":"2024-07-02T16:35:15.156Z","phase":"Phase 2","brief_title":"Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors","source_id_and_acronym":"NCT02100891 - STIR Trial","lead_sponsor":"Monica Thakar","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 03/20/2013","start_date":" 03/20/2013","primary_txt":" Primary completion: 06/08/2020","primary_completion_date":" 06/08/2020","study_txt":" Completion: 07/15/2020","study_completion_date":" 07/15/2020","last_update_posted":"2024-03-12"}]